08:31 AM EDT, 05/07/2025 (MT Newswires) -- Knight Therapeutics ( KHTRF ) on Wednesday said it is relaunching Onicit IV (palonosetron) in Brazil and Mexico, through its affiliates in those countries.

A statement noted Onicit solution for injection is approved and marketed in Brazil and Mexico for the prevention of acute nausea and vomiting associated with adults undergoing chemotherapy for cancer. The solution is also indicated for the prevention of postoperative nausea and vomiting for up to 24 hours after surgery. In Brazil, Onicit is also indicated for pediatric patients, from 1 month to 17 years of age undergoing chemotherapy treatment.

"We are proud to continue providing patients and health care professionals with advanced treatments like ONICIT to help mitigate the debilitating effects of chemotherapy induced nausea and vomiting," said Samira Sakhia, chief executive officer.